DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.

Author(s): Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R

Affiliation(s): Division of Hematology and Bone Marrow Transplantation, Department of Medical and Morphological Researches, Azienda Ospedaliero-Universitaria, P.zzale S. M. Misericordia, 15, 33100 Udine, Italy. mario.tiribelli@uniud.it

Publication date & source: 2009-01, Leuk Res., 33(1):174-7. Epub 2008 May 8.

Publication type: Case Reports

Prognosis of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation (SCT) is dismal. Immunotherapy with donor lymphocyte infusion (DLI) and imatinib are rarely and/or transiently effective. Here we describe the case of a patient with imatinib-resistant post-transplant relapse of ALL, who received a combination of standard dose nilotinib and monthly DLI infusion. Therapy was well tolerated and the patient achieved and maintained a complete molecular remission. Our case provides a rationale for the combined use of a second line tyrosine kinase inhibitor and DLI in the treatment of relapsed Ph+ ALL.

Page last updated: 2009-02-08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017